Shots: Ironwood to receive three non-contingent payment of $35M b/w 2021 & 2024, ~$90M as a milestone with royalties on sales of Linzess in China mainland, China Hong Kong and China Macau. AstraZeneca to get full rights to develop, manufacture & commercialize Linzess in China In Oct’2012, the companies collaborated to co-develop and co-commercialize Linzess […]Read More
Shots: The approval is based on P-III study results assessing Linzess (290 mcg) vs PBO in 839 patients in ratio the (1:1) with IBS-C in adults for 12 weeks The P-III study demonstrated 1EP & 2EP as Abdominal Pain/Discomfort Responders (60% vs 48.8%) & IBS Degree of Relief Responders (31.7% vs 15.4%) respectively Linaclotide is […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
